SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Burke Steven Keith   |   |       | 2. Date of Event<br>Requiring Statement<br>(Month/Day/Year)<br>10/21/2014 |   | 3. Issuer Name and Ticker or Trading Symbol PROTEON THERAPEUTICS INC [ PRTO ]   |   |  |  |  |  |
|--|---|-------|---|---|---|---|--|--|--|--|
| (Last) (First) (Middle)<br>C/O PROTEON THERAPEUTICS<br>200 WEST STREET<br>(Street)<br>WALTHAM MA 02451 |   |       |   |   | 4. Relationship of Reporting Per<br>(Check all applicable)<br>Director<br>X Officer (give title<br>below)<br>Sr. VP & Chief Mec | 10% Owne<br>Other (spe<br>below)  | r (Mor<br>cify 6. In<br>App  | hth/Day/Year)<br>dividual or Joint<br>icable Line)<br>Form filed b | te of Original Filed<br>/Group Filing (Check<br>y One Reporting Person<br>y More than One<br>erson |  |
| (City)   | (State)   | (Zip) |   |   |   |   |  |  |  |  |
|  |   |       | Table I - No  | n-Derivati  | ive Securities Beneficia  | lly Owned   |  |  |  |  |
| 1. Title of Security (Instr. 4)  |   |       |   |   | . Amount of Securities<br>Seneficially Owned (Instr. 4)   | 3. Ownersh<br>Form: Direc<br>or Indirect (<br>(Instr. 5)  | Direct (D) (Instr. 5)<br>rect (I)  |  | Beneficial Ownership   |  |
|  |   | (e.   |   |   | e Securities Beneficially<br>Ints, options, convertibl  |   | 5)   |  |  |  |
| 1. Title of Derivative Security (Instr. 4)   |   |       | 2. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year)            |   | 3. Title and Amount of Securities<br>Underlying Derivative Security (Instr. 4)  |   | 4.<br>Conversion<br>or Exercise  | 5.<br>Ownership<br>Form:   | 6. Nature of Indirect<br>Beneficial Ownership<br>(Instr. 5)  |  |
|  |   |       |   | 1   |   |   |  |  | (Instr. 5)   |  |
|  |   |       | Date<br>Exercisable   | Expiration<br>Date  | Title   | Amount<br>or<br>Number<br>of Shares   | Price of<br>Derivative<br>Security   | Direct (D)<br>or Indirect<br>(I) (Instr. 5)                        | (Instr. 5)   |  |
| Stock Option (   | Right to Buy)                                   |       |   |   |   | or<br>Number  | Derivative   | Direct (D)<br>or Indirect  | (Instr. 5)   |  |
| Stock Option (<br>Stock Option (   |   |       | Exercisable   | Date  | Title   | or<br>Number<br>of Shares   | Derivative<br>Security   | Direct (D)<br>or Indirect<br>(I) (Instr. 5)                        | (Instr. 5)   |  |
|  | Right to Buy)                                   |       | Exercisable (1)   | Date<br>08/01/2016  | Title Common Stock  | or<br>Number<br>of Shares<br>30,411 <sup>(4)</sup>  | Derivative<br>Security<br>1.905 <sup>(4)</sup>   | Direct (D)<br>or Indirect<br>(I) (Instr. 5)                        | (Instr. 5)   |  |
| Stock Option (   | Right to Buy)<br>Right to Buy)                  |       | (1)<br>(1)  | Date<br>08/01/2016<br>09/10/2017                                    | Title       Common Stock       Common Stock   | or<br>Number<br>of Shares           30,411 <sup>(4)</sup> 12,287 <sup>(4)</sup>                       | Derivative<br>Security<br>1.905 <sup>(4)</sup><br>2.381 <sup>(4)</sup>                         | Direct (D)<br>or Indirect<br>(I) (Instr. 5)                        | (Instr. 5)   |  |
| Stock Option (<br>Stock Option (   | Right to Buy)<br>Right to Buy)<br>Right to Buy) |       | Exercisable           (1)           (1)           (1)                     | Date           08/01/2016           09/10/2017           06/19/2019 | Title       Common Stock       Common Stock       Common Stock  | or<br>Number<br>of Shares           30,411 <sup>(4)</sup> 12,287 <sup>(4)</sup> 14,898 <sup>(4)</sup> | Derivative<br>Security<br>1.905 <sup>(4)</sup><br>2.381 <sup>(4)</sup><br>3.174 <sup>(4)</sup> | Direct (D)<br>or Indirect<br>(I) (Instr. 5)<br>D<br>D<br>D         | (Instr. 5)   |  |

Explanation of Responses:

1. The shares underlying these options are fully vested.

2. This option is fully exercisable prior to its vesting, subject to a repurchase right held by the Issuer on the shares underlying this option that lapses (based on the original option vesting schedule) in equal quarterly installments over four years.

3. This option is fully exercisable prior to its vesting, subject to a repurchase right held by the Issuer on the shares underlying this option that lapses (based on the original option vesting schedule) 25% on the first anniversary of the grant date and the remaining shares in equal quarterly installments over the next three years.

4. Reflects a 1-for-15.87 reverse stock split effected on October 6, 2014.

#### **Remarks:**

Exhibit 24.1 Power of Attorney

### /s/ Steven K. Burke

\*\* Signature of Reporting Person

10/21/2014

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

## **PROTEON THERAPEUTICS, INC.**

#### POWER OF ATTORNEY

KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Timothy P. Noyes, George A. Eldridge and Dean Profis, each individually, as the undersigned's true and lawful attorneys-in-fact to:

(1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Proteon Therapeutics, Inc. (the "<u>Company</u>"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;

(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of any such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by any such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorneys-in-fact, or such attorneys-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that each of the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

By this Power of Attorney, the undersigned hereby revokes all prior Powers of Attorney authorizing any person to sign any documents in the name of the undersigned related to Section 16 and the Company.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to each of the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 21st day of October, 2014.

/s/ Steven K. Burke Steven K. Burke

[Signature Page to Power of Attorney for S. Burke]